{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:28:42Z","timestamp":1791052122842,"version":"4.1.0"},"reference-count":50,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"abstract":"<jats:p>Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy. Routes to the identification of biomarkers have been recognized by known molecular features of the disease and more recently through transcriptomic, methylation and proteomic screening approaches. The majority of Barrett's oesophagus patients remain undiagnosed in the general population. In order to develop a tool to screen for Barrett's oesophagus in the primary care setting, minimally invasive sampling methods coupled with immunocytology-based biomarkers are currently being assessed. Biomarkers may also have utility in surveillance programmes by allowing endoscopic interval to be adjusted according to individual neoplastic risk. Many individual biomarkers have been proposed in this regard, but have frequently been assessed in studies of limited power, or have lacked sufficient sensitivity or specificity when assessed in wider population-based studies. Biomarker panels may provide a route forward. In this regard, a panel of methylation markers has shown promise in a multicentre, double-blind, validation study. Biomarkers are also being developed to improve detection of high-grade dysplasia and oesophageal adenocarcinoma, utilizing brush cytology combined with FISH (fluorescence in situ hybridization), and to assess therapeutic success and risk of complication during photodynamic therapy. Finally, we outline progress in identifying alternative sources of biomarkers for this condition.<\/jats:p>","DOI":"10.1042\/bst0380343","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T14:16:27Z","timestamp":1269440187000},"page":"343-347","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biomarkers in Barrett's oesophagus"],"prefix":"10.1042","volume":"38","author":[{"given":"Qizhi","family":"Huang","sequence":"first","affiliation":[{"name":"Molecular Epidemiology Unit, Leeds Institute of Genetics, Health and Therapeutics, LIGHT Laboratories, University of Leeds, Leeds LS2 9JT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura\u00a0J.","family":"Hardie","sequence":"additional","affiliation":[{"name":"Molecular Epidemiology Unit, Leeds Institute of Genetics, Health and Therapeutics, LIGHT Laboratories, University of Leeds, Leeds LS2 9JT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2010,3,22]]},"reference":[{"key":"2021111720542846000_B1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc1166","article-title":"Reflux, Barrett's oesophagus and adenocarcinoma: burning questions","volume":"3","author":"Wild","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"2021111720542846000_B2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ajg.2008.172","article-title":"Biomarkers in gastroenterology: between hope and hype comes histopathology","volume":"104","author":"Jankowski","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"2021111720542846000_B3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2302\/kjm.58.12","article-title":"Surveillance in Barrett's esophagus: a failed premise","volume":"58","author":"Inadomi","year":"2009","journal-title":"Keio J. Med."},{"key":"2021111720542846000_B4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/gut.2009.180281","article-title":"Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic","volume":"58","author":"Lao-Sirieix","year":"2009","journal-title":"Gut"},{"key":"2021111720542846000_B5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-03-2438","article-title":"Biomarkers of esophageal adenocarcinoma and Barrett's esophagus","volume":"64","author":"McManus","year":"2004","journal-title":"Cancer Res."},{"key":"2021111720542846000_B6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","article-title":"Phases of biomarker development for early detection of cancer","volume":"93","author":"Pepe","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"2021111720542846000_B7","first-page":"99","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"28","author":"McShane","year":"2006","journal-title":"Exp. Oncol."},{"key":"2021111720542846000_B8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00268-003-7052-2","article-title":"Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction","volume":"27","author":"Pera","year":"2003","journal-title":"World J. Surg."},{"key":"2021111720542846000_B9","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1053\/j.gastro.2005.08.053","article-title":"Prevalence of Barrett's esophagus in the general population: an endoscopic study","volume":"129","author":"Ronkainen","year":"2005","journal-title":"Gastroenterology"},{"key":"2021111720542846000_B10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/gcc.20543","article-title":"Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens","volume":"47","author":"Rygiel","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"2021111720542846000_B11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/gast.2000.9302","article-title":"Is there publication bias in the reporting of cancer risk in Barrett's esophagus?","volume":"119","author":"Shaheen","year":"2000","journal-title":"Gastroenterology"},{"key":"2021111720542846000_B12","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-03-3249","article-title":"Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus","volume":"64","author":"Maley","year":"2004","journal-title":"Cancer Res."},{"key":"2021111720542846000_B13","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1572-0241.2001.04236.x","article-title":"Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression","volume":"96","author":"Reid","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"2021111720542846000_B14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/gut.2005.083295","article-title":"TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort","volume":"55","author":"Murray","year":"2006","journal-title":"Gut"},{"key":"2021111720542846000_B15","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2001.05261.x","article-title":"Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables","volume":"96","author":"Rabinovitch","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"2021111720542846000_B16","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.1158\/1078-0432.CCR-07-5063","article-title":"Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with barrett's esophagus: a long-term prospective study","volume":"14","author":"Chao","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2021111720542846000_B17","first-page":"2560","article-title":"Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus","volume":"9","author":"Sirieix","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"2021111720542846000_B18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1078-0432.CCR-06-1385","article-title":"Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance","volume":"13","author":"Lao-Sirieix","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2021111720542846000_B19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.athoracsur.2003.09.051","article-title":"Gene expression profiles in esophageal adenocarcinoma","volume":"77","author":"Dahlberg","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"2021111720542846000_B20","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/sj.onc.1209357","article-title":"Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"2021111720542846000_B21","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1021\/pr7007835","article-title":"Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo\u2013keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma","volume":"7","author":"Breton","year":"2008","journal-title":"J. Proteome Res."},{"key":"2021111720542846000_B22","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1038\/sj.onc.1208598","article-title":"Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk","volume":"24","author":"Schulmann","year":"2005","journal-title":"Oncogene"},{"key":"2021111720542846000_B23","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-09-0028","article-title":"A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus","volume":"69","author":"Jin","year":"2009","journal-title":"Cancer Res."},{"key":"2021111720542846000_B24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/carcin\/bgm241","article-title":"A pro-inflammatory genotype predisposes to Barrett's esophagus","volume":"29","author":"Moons","year":"2008","journal-title":"Carcinogenesis"},{"key":"2021111720542846000_B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/GIM.0b013e3180654ccd","article-title":"The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma","volume":"9","author":"di\u00a0Martino","year":"2007","journal-title":"Genet. Med."},{"key":"2021111720542846000_B26","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/carcin\/bgi115","article-title":"Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma","volume":"26","author":"Casson","year":"2005","journal-title":"Carcinogenesis"},{"key":"2021111720542846000_B27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00109-007-0271-5","article-title":"Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus","volume":"86","author":"Hennig","year":"2008","journal-title":"J. Mol. Med."},{"key":"2021111720542846000_B28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.gie.2005.06.047","article-title":"Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial","volume":"62","author":"Overholt","year":"2005","journal-title":"Gastrointest. Endosc."},{"key":"2021111720542846000_B29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.gie.2006.12.037","article-title":"Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia","volume":"66","author":"Overholt","year":"2007","journal-title":"Gastrointest. Endosc."},{"key":"2021111720542846000_B30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1053\/j.gastro.2008.04.036","article-title":"Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus","volume":"135","author":"Prasad","year":"2008","journal-title":"Gastroenterology"},{"key":"2021111720542846000_B31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/cncr.23573","article-title":"Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus","volume":"113","author":"Prasad","year":"2008","journal-title":"Cancer"},{"key":"2021111720542846000_B32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2007.09.006","article-title":"ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer","volume":"44","author":"Kim","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"2021111720542846000_B33","first-page":"2579","article-title":"Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus","volume":"24","author":"Heeren","year":"2004","journal-title":"Anticancer Res."},{"key":"2021111720542846000_B34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1010-7940(02)00044-1","article-title":"Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer","volume":"21","author":"Imdahl","year":"2002","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"2021111720542846000_B35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.sla.0000118751.95179.c6","article-title":"NF-\u03baB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy","volume":"239","author":"Abdel-Latif","year":"2004","journal-title":"Ann. Surg."},{"key":"2021111720542846000_B36","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1158\/1078-0432.CCR-04-2373","article-title":"High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer","volume":"11","author":"Xi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2021111720542846000_B37","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11605-008-0668-7","article-title":"ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus","volume":"12","author":"Brabender","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"2021111720542846000_B38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jso.21355","article-title":"Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer","volume":"100","author":"Grimminger","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"2021111720542846000_B39","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2005.03.6640","article-title":"Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer","volume":"24","author":"Wu","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2021111720542846000_B40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/tpj.2009.5","article-title":"GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer","volume":"9","author":"Alakus","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"2021111720542846000_B41","doi-asserted-by":"crossref","first-page":"804108","DOI":"10.1155\/2009\/804108","article-title":"Anti-EGFR-targeted therapy for esophageal and gastric cancers: an evolving concept","volume":"2009","author":"Dragovich","year":"2009","journal-title":"J. Oncol."},{"key":"2021111720542846000_B42","first-page":"347","article-title":"Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach","volume":"54","author":"Villanacci","year":"2008","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"2021111720542846000_B43","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1055-9965.EPI-06-0492","article-title":"Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis","volume":"15","author":"Chao","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2021111720542846000_B44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1940-6207.CAPR-08-0227","article-title":"Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer","volume":"2","author":"Xing","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"2021111720542846000_B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2004.12.008","article-title":"Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?","volume":"49","author":"Bremnes","year":"2005","journal-title":"Lung Cancer"},{"key":"2021111720542846000_B46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2407-9-288","article-title":"Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment","volume":"9","author":"Sun","year":"2009","journal-title":"BMC Cancer"},{"key":"2021111720542846000_B47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ejso.2006.02.015","article-title":"The detection of oesophageal adenocarcinoma by serum microsatellite analysis","volume":"32","author":"Eisenberger","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"2021111720542846000_B48","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00432-009-0564-x","article-title":"Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome","volume":"135","author":"Hoffmann","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2021111720542846000_B49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.athoracsur.2007.03.088","article-title":"Diagnosis of esophageal adenocarcinoma by serum proteomic pattern","volume":"84","author":"Hammoud","year":"2007","journal-title":"Ann. Thorac. Surg."},{"key":"2021111720542846000_B50","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/pr8008385","article-title":"Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets","volume":"8","author":"Mechref","year":"2009","journal-title":"J. Proteome Res."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/38\/2\/343\/517153\/bst0380343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/38\/2\/343\/517153\/bst0380343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:42:21Z","timestamp":1637199741000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/38\/2\/343\/67129\/Biomarkers-in-Barrett-s-oesophagus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,22]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,3,22]]},"published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bst0380343","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,22]]}}}